The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.
Cuixia Yang,Jie Lv,Xiangrui Jiang,Zhenglong Xiang,Ran Gong,Jiahua Xing,Guangyu Liu,Ling Xie,Kandireya Saimaier,Yan Zhang,Junjian Wang,Hu Shen,Juping Pan,Jingshan Shen,Changsheng Du
DOI: https://doi.org/10.1038/s41423-020-00566-8
2020-01-01
Abstract:Multiple sclerosis(MS)is a predominantly T-cell-mediated auto-immune inflammatory disease of the central nervous system(CNS)characterized by multifocal areas of immune cell infiltration,demyelination,axonal damage,and disruption of neuronal signal.1,2 It is now widely accepted that MS is a heterogeneous,multifactorial disease influenced by genetic,epigenetic,and environmental factors.3 Now,subsequent studies have identified and highlighted an important pathogenic role for Th17 cells in autoimmunity,a kind of CD4+T-cell subset that secrete signature cytokine interleukin IL-17A.4,5 However,the treatment for MS still remains a great challenge.Thus,the current prompted us to find a more effective disease-modifying treatment.Here,we found that small-molecule TPN10456 potently suppressed Th17 cell differentiation.Interestingly,TPN10456 inhibited pathogenic Th17 cells differentiation,but not conventional Th17 cells.Meanwhile,TPN 10456 also inhibited human Th17 cells differentiation in vitro.Moreover,compared with the vehicle group,TPN 10456-treated EAE mice showed less severe EAE symptoms,including lower clinical scores,reduced inflammatory cells infiltration,and less extensive demyelination in CNS.These results suggest that TPN 10456 may represent a promising therapeutic agent for the treatment of MS.